Search

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ --Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's [...]

Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy Fulphila is the [...]

Innovative Neulasta Onpro Kit is Designed to Provide the Right Dose for Patients at the Right Time THOUSAND OAKS, Calif., Feb. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that [...]

- Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine - Pegfilgrastim is a long-acting version of the oncology [...]

Unique Campaign Highlights the Importance of Understanding Your Treatment and Building a Support Community, With Advice From Joan Lunden, Cancer Survivors and Healthcare Professionals Campaign Encourages Patients to Advocate for [...]

Online News Resource Highlights Importance of Patient and Care Team Dialogue THOUSAND OAKS, Calif., April 18, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Neulasta (pegfilgrastim) Onpro [...]

Second Successful BLA Filing of the Partnership in the U.S. HERTFORDSHIRE, England, PITTSBURGH and®BENGALURU, India, Feb. 16, 2017 /PRNewswire/ --®Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, [...]

New Analysis From Phase 3 Trial of Kyprolis (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease Progression Phase 1/3 MASTERKEY-265 Study Abstracts Present Data on IMLYGIC (Talimogene [...]

First Quarter 2016 GAAP EPS Were $2.50 2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen [...]

Approval Has Implications for Public Health and National Security BALTIMORE, Jan. 20, 2016 /PRNewswire-USNewswire/ -- As a result of research performed by scientists at the University of Maryland School of [...]

Data Underscore Company's Commitment to Difficult-to-Treat Blood Cancers New Insights Further Strengthen Evidence of the Role of Kyprolis (Carfilzomib) in Relapsed Multiple Myeloma Growing Body of Clinical Evidence Validates Immunotherapy [...]

Third Quarter 2015 GAAP EPS Increased 52 Percent to $2.44 2015 Total Revenues and Adjusted EPS Guidance Increased to $21.4-$21.6 Billion and $9.95-$10.10, Respectively Preliminary 2016 Total Revenues and Adjusted [...]

Showcasing New Data in Solid Tumors and Supportive Care THOUSAND OAKS, Calif., Sept. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it will present data from its oncology portfolio and [...]

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ [...]

Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta TORONTO, Dec. 17, 2014 /CNW/ - Apotex Inc., the largest Canadian owned pharmaceutical [...]

Third Quarter 2014 GAAP EPS Were $1.61 2014 Total Revenues and Adjusted EPS Guidance Increased to $19.8-$20.0 Billion and $8.45-$8.55, Respectively THOUSAND OAKS, Calif., Oct. 27, 2014 /PRNewswire/ -- Amgen [...]

2014 Revenue and Adjusted EPS Guidance Reaffirmed THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include: [...]

Third Quarter 2013 GAAP EPS Were $1.79 2013 Total Revenues and Adjusted EPS Guidance Increased to $18.3-$18.5 Billion and $7.35-$7.45 THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) [...]

THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ('Roche') to acquire Roche's rights to [...]

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p01595427/Biosimilar-Opportunities-in-an-Evolving-Market http://www.reportlinker.com/p01595427/Biosimilar-Opportunities-in-an-Evolving-Market .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biosimilars: another milestone passed At the end [...]

Second Quarter 2013 GAAP EPS Were $1.65 2013 Total Revenues and Adjusted EPS Guidance Increased to the Upper End of $17.8-$18.2 Billion and $7.30-$7.45 THOUSAND OAKS, Calif., July 30, 2013 [...]

Study Shows Neulasta Reduced the Incidence of Febrile Neutropenia in Patients With Colorectal Cancer Receiving FOLFOX or FOLFIRI and Bevacizumab THOUSAND OAKS, Calif., Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) [...]

Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge 2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion [...]

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0657325/Biosimilar/Follow-on-Biologics-Market-Report--Forecast-A-Focus-on-the-US-(2011-2020).html http://www.reportlinker.com/p0657325/Biosimilar/Follow-on-Biologics-Market-Report--Forecast-A-Focus-on-the-US-2011-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical With sales worth US$ 57 Million in 2010, [...]

NEW YORK, Aug. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0578541/Pre-Filled-Syringes-World-Market-Outlook-2011-2021.html http://www.reportlinker.com/p0578541/Pre-Filled-Syringes-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic How will the pre-filled syringes market develop this [...]

Second Quarter 2011 Product Sales Increased 8 Percent to $3.9 Billion Second Quarter 2011 Adjusted and GAAP Earnings Per Share (EPS) Were $1.37 and $1.25, Respectively Amgen Announced its First [...]

Final Results From The Largest And Longest Study Of Nplate For The Treatment Of Adult Chronic ITP To Be Presented Amgen Expands Amgen FIRST STEP(TM) Program Co-Pay Coupon Benefits To [...]

THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European [...]

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, [...]

Company's INS-20 Receives Regulatory Clearance to Begin Phase I Clinical Trial RICHMOND, Va., Oct. 14 /PRNewswire-FirstCall/ -- Insmed Inc. , a developer of follow-on biologics and biopharmaceuticals, today announced that [...]

- Company on Schedule to Have Two Follow-on Biologics in Clinical Studies by Year-End - Enrollment On Track in MMD Clinical Study - ALS Expanded Access Program Continues to Enroll [...]